Diagnostics; making a difference

Member Press Releases

Current Articles | Categories | Search | Syndication

22 September 2016  
AgPlus Diagnostics to Develop Point-­‐of-­‐Care Test for AstraZeneca
By @ 10:54 :: 41 Views

AgPlus Diagnostics Ltd today announced that they have signed a contract with AstraZeneca to develop a prototype diagnostic. The agreement will cover AgPlus Diagnostics developing a diagnostic assay for potential use as part of a personalised approach to treating respiratory disease.
Read More

22 September 2016  
Study Demonstrates Mass Spectrometry Technique Dramatically Enhances Detection of Key Early Stage Alzheimer’s Biomarkers.
By @ 09:17 :: 42 Views

For immediate release: 22nd September 2016, Cobham, UK: A peer reviewed study led by Proteome Sciences plc (“Proteome Sciences”), in conjunction with a group of highly respected universities and hospitals, demonstrates the ability of an innovative mass spectrometry (MS) workflow to dramatically improve the ability to detect tau-derived peptides that are directly related to human Alzheimer’s pathology as early stage biomarkers of the disease.

Read More

22 September 2016  
RGC Jenkins & Co announces merger with German firm, Maucher Börjes Jenkins
By @ 09:06 :: 76 Views


Specialist intellectual property firm, RGC Jenkins & Co has announced this week that it is merging with Freiburg firm, Maucher Börjes Jenkins to become Maucher Jenkins.

Read More

19 September 2016  
Beckman Coulter installs UK’s first DxH 500 compact haematology analyser at University of Chester Institute of Medicine
By @ 14:15 :: 52 Views


New simple-to-use 5-part diff DxH 500 ideal for wide-ranging applications

Read More

15 September 2016  
By @ 09:16 :: 39 Views

Proteome Sciences today releases its unaudited interim results for the six months ended 30th June 2016.

Read More

13 September 2016  Joanne Hunter
OGT expands Cytocell FISH probe portfolio for lung cancers
By Joanne Hunter @ 11:16 :: 81 Views

Oxford, UK – 13 September 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The Cytocell Aquarius® ROS1 Plus Breakapart and RET Breakapart probes* specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC). The new additions complement OGT’s existing NSCLC probe range (including ALK Breakapart, EGFR Amplification and EML Breakapart), providing a comprehensive solution for diagnosis and patient stratification.

Read More

01 September 2016  Rachel Myers
By Rachel Myers @ 17:25 :: 102 Views :: 2016

® Malaria Receives 1 st Place Award at the Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris

Meridian Bioscience, Inc. (NASDAQ: VIVO) was awarded 1st place for innovation in emergency treatment and point-of-care testing for its illumigene® Malaria test at the 2016 JIB/ACNBH Conference. Innovations from worldwide companies contributing to the development of the Medical Biology industry were put under the spotlight at this year’s conference held in Paris, France, and were reviewed by worldwide expert members in the medical biology field. 

Read More

29 July 2016  
BBI Solutions extends its antibodies range
By @ 11:07 :: 161 Views :: 2016

BBI Solutions (BBI) has vastly increased its antibodies range across a wide variety of disease areas including bone metabolism, cardiac, growth factors, thyroid, and sepsis. This range extension has been in response to growing demand in the IVD market. 

Read More

28 July 2016  
Trading Update and Notice of Results
By @ 10:30 :: 154 Views :: 2016

The Company is pleased to provide a trading update for the six months ending 30th June 2016.  

Read More

25 July 2016  
Cytox launches breakthrough genetic biomarker research assay for Alzheimer’s disease
By @ 11:52 :: 161 Views :: 2016

Simple blood-based test will help reduce screening failure in clinical trials and assist drug discovery
Read More

Previous Page | Next Page